Executive Director, Market Access GI, Europe

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Executive Director, Value, Market Access & Pricing (GI) will lead the development and execution of European market access and pricing strategies for Revolution Medicines’ gastrointestinal oncology portfolio.

This role will be responsible for ensuring that payer, HTA, and policy requirements across Europe are fully embedded into product strategy, evidence generation, and launch planning—while aligned with Global Value, Access & Pricing strategies, frameworks, and governance.

Reporting to the VP, Value, Market Access & Pricing Europe, the role serves as the primary European access strategy owner for GI, partnering closely with Global, Regional, and Country teams to drive timely, sustainable patient access across European markets.

Key Responsibilities

European Value, Access & Pricing Strategy

• Lead and own the European market access and pricing strategy for GI indications, with significant focus on PDAC, ensuring optimal reimbursement and access outcomes across the EU and key European markets.

• Collaborate with Regional and Country Commercial, Medical and Regulatory teams to shape the overall GI strategy, projects and launch plans.

• Translate global value strategy, Target Product Profiles (TPPs), and pricing principles into executable European access plans, value dossiers and economic models, while providing structured input to inform global strategy evolution.

• Shape and localize the European value narrative for GI, ensuring alignment with the Global Value Dossier (GVD) and relevance to national HTA requirements.

• Define and execute European launch sequencing, net price corridors, and reference pricing mitigation strategies, in alignment with global pricing governance.

• Identify, assess, and proactively manage Europe-specific access risks and opportunities across GI indications, escalating insights to global and regional leadership as appropriate.

• Contribute to the JCA dossier in collaboration with the ED, European JCA Oncology.

Evidence Generation & Development Alignment

• Partner with Clinical Development, HEOR, Regulatory, and Medical Affairs to ensure European payer and HTA evidence needs are embedded into GI development programs.

• Provide European leadership on study design, endpoint selection, comparators, lines of therapy, and sub-population strategies to support successful HTA and reimbursement outcomes.

Launch Readiness & Market Execution

• Lead European payer research and stakeholder engagement, translating insights into actionable access strategies.

• Partner with regional and country teams to drive launch readiness, including access roadmaps, affiliate enablement, and negotiation strategy support.

• Partner with regional and global commercial teams to contribute to forecasting and payer research.

Cross-Functional & Regional Leadership

• Serve as the European access lead for GI on global asset and launch teams, representing regional needs while reinforcing global alignment.

• Act as a strategic thought partner to Commercial, Medical, Regulatory, HEOR, and Global Access leadership on GI market dynamics and implications.

Policy, Risk & External Engagement

• Monitor and assess European pricing, HTA, and policy trends relevant to GI oncology, translating implications into lifecycle and access strategies.

• Coordinate closely with Global and U.S. access teams to ensure policy and pricing alignment, particularly where European decisions may impact global pricing corridors or lifecycle management.

Required Skills, Experience and Education:

• Bachelor’s degree required; advanced degree in Health Economics, Pharmacy, Life Sciences, Public Health, or Business preferred.

• 15+ years of experience in European market access, pricing, and HTA leadership within the biopharma or biotech industry.

• Proven success leading European launches of specialty or oncology products, including GI indications.

• Deep expertise in European payer systems and HTA processes, including AMNOG, NICE, HAS, AIFA, and EU-level HTA collaborations.

• Demonstrated ability to influence clinical development and global strategy through regional access insights.

• Strong track record of working effectively in matrixed, global organizations, balancing regional accountability with global alignment.

Preferred Skills:

• EU market access experience with a strong focus on oncology.

• Experience supporting first-in-class or highly innovative therapies.

• Strong executive presence with the ability to clearly articulate complex value propositions to internal and external stakeholders.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact privacy@revmed.com. 

#LI-Remote #LI-LO1